- Oxygen Biotherapeutics' (OXBT) Levosimendan product significantly improves post-operative kidney function in patients who have undergone surgery of the mitral valve in the heart, evidence from a study published in the Journal of Cardiothoracic & Vascular Anesthesia shows.
- Oxygen Biotherapeutics expects to begin a Phase III trial of Levosimendan in Q3 for patients undergoing coronary artery by-pass and or mitral valve surgery.
- Shares +22%. (PR)
Oxygen shares soar following positive Levosimendan data
Feb 13 2014, 09:45 ET